We are a group focused on the development of in vitro disease models. We have integrated these models with microfluidic systems and biosensors, which allow us to monitor the behavior and progression of tissues for extended periods (over 30 days). Our portfolio includes 3D skeletal muscle models for sarcopenia, Duchenne muscular dystrophy, and DM1 dystrophy. Additionally, we have developed a 3D liver model for NAFLD and DILI, as well as a 3D pancreatic model.

We can determine the in vitro efficacy of exogenous nutraceuticals (such as antioxidants and ketone bodies) on skeletal muscle to activate mitochondrial activity by analyzing reactive oxygen species. We also study their effects on liver (both healthy and disease models) and pancreas. Furthermore, we investigate the impact of exercise on muscle energy metabolism and its potential benefits on the liver and pancreas.

The Institute of Bioengineering of Catalonia (IBEC) in Barcelona is a research center focused on interdisciplinary studies at the intersection of engineering and life sciences, integrating fields like nanomedicine, biotechnology, tissue engineering, and health technology applications.
I am Javier Ramon, Group Leader at IBEC since 2017. My team, 'Biosensors for Bioengineering,' focuses on integrating sensor technology and nanotechnology with tissue engineering to develop organs-on-a-chip (OOC). We aim to create functional tissues combined with microscale biosensors. Our team consists of 21 members, including postdocs, PhD students, and specialized technicians.
A key project is the ERC-funded “DAMOC,” which aims to develop a multi-organ-on-a-chip platform mimicking in vivo tissue properties, to advance research in type 2 diabetes (T2D) and muscular dystrophy. Another significant project is “TATAMI,” funded by Fundación Bancaria "La Caixa" CaixaHealth, which develops models for muscular dystrophies to understand molecular pathogenesis and identify therapeutic targets. Using advanced biomimetic models and biosensors, we have identified leads for treating myotonic dystrophy 1 (DM1). This project involves collaborations with Professor Ruben Artero (INCLIVA) and Dr. Vilchez (Hospital de la Fe, Valencia).
I have established collaborations with researchers, clinicians, and companies worldwide. For instance, I secured funding from the UK’s Medical Research Council to study Duchenne muscular dystrophy. I also collaborate with teams at Hospital de Sant Pau (Barcelona) and with Professor Eduard Gallardo’s group to study myasthenia gravis. Additionally, in the SIC-BIO project with Professor Josep Samitier, we are developing cell encapsulation and sensing systems integrated with organs-on-a-chip.
Our research aims to create more accurate and scalable in vitro models, advancing drug discovery, disease understanding, and personalized medicine.